Anti SARS-CoV-2 antibodies monitoring in a group of residents in a long term care facility during COVID-19 pandemic peak.


Journal

Diagnosis (Berlin, Germany)
ISSN: 2194-802X
Titre abrégé: Diagnosis (Berl)
Pays: Germany
ID NLM: 101654734

Informations de publication

Date de publication:
18 Nov 2020
Historique:
received: 08 07 2020
accepted: 08 07 2020
pubmed: 23 8 2020
medline: 27 11 2020
entrez: 23 8 2020
Statut: ppublish

Résumé

Objectives Clinical laboratories plays a key role in screening, diagnosis and containment of the Coronavirus 2019 infection epidemic. The etiological diagnosis presupposes the isolation of virus genetic material in the patient's biological sample but laboratory diagnostics also make use of searching possibility for immunoglobulin (Ig)G, IgM classes antibodies. The characteristics of the antibody response are not yet completely clear. Methods This study describes a serological monitoring of subjects, elderly nursing care residence guests, interested by a very large infection outbreak. After first nasopharyngeal swab, all the positive subjects (43) were monitored for the persistence of the virus infection through nasopharyngeal swab after 20 days (16-24), 32 days (28-36) and after 49 days (47-50). At the same time, during the second (day 32) and third (day 49) follow up, all the guests were investigated for IgM and IgG anti SARS-CoV-2 antibodies, by using a quantitative chemiluminescence method. Results Thirty two days after performing the first diagnostic swab, 39 of 43 patients (90%) had IgG higher than the cut off value. After 49 days the four patients with negative IgG were still negative. The comparison of the levels of IgG-Ab between the controls shows a significant decrease in concentrations (-10%). Conclusions Our study confirms that in most patients affected by COVID-19 there is a typical antibody response with IgG-Ab present in 90% of nursing care COVID-19 positive residence guests. For IgM-Ab only 23% of tested subjects were positive on the 32nd and 49th day of illness, always in parallel with the IgG-Ab positivity.

Identifiants

pubmed: 32827394
doi: 10.1515/dx-2020-0094
pii: dx-2020-0094
doi:

Substances chimiques

Immunoglobulin G 0
Immunoglobulin M 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

395-400

Références

Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol 2020;5:536–44. https://doi.org/10.1038/s41564-020-0695-z.
Jiang, F, Deng, L, Zhang, L, Cai, Y, Cheung, CW, Xia, Z. Review of the clinical characteristics of coronavirus disease 2019 (COVID-19). J Gen Int Med 2020;35:1545–9. https://doi.org/10.1007/s11606-020-05762-w.
Chen, Y, Liu, Q, Guo, D. Emerging coronaviruses: genome structure, replication, and pathogenesis. J Med Virol 2020;92:418–23. https://doi.org/10.1002/jmv.25681.
Maragakis, L. Coronavirus and COVID-19: who is at higher risk?. Johns Hopkins Med 2020. Available from: https://www.hopkinsmedicine.org/health/conditions-and-diseases/coronavirus/coronavirus-and-covid19-who-is-at-higher-risk.
Plebani, M. Il valore della medicina di laboratorio nella pandemia da SARS-CoV-2. Biochim Clin 2020;1–5. https://doi.org/10.19186/BC_2020.053 [Epub ahead of print].
Lippi, G, Simundic, AM, Plebani, M. Potential preanalytical and analytical vulnerabilities in the laboratory diagnosis of coronavirus disease 2019 (COVID-19). Clin Chem Lab Med 2020;58:1070–6. https://doi.org/10.1515/cclm-2020-0285.
Padoan, A, Sciacovelli, L, Basso, D, Negrini, D, Zuin, S, Cosma, C, et al.. IgA-Ab response to spike glycoprotein of SARS-CoV-2 in patients with COVID-19: a longitudinal study. Clin Chim Acta 2020;507:164–6. https://doi.org/10.1016/j.cca.2020.04.026.
Theel, ES, Slev, P, Wheeler, S, Couturier, MR, Wong, SJ, Kadkhoda, K. The role of antibody testing for SARS-CoV-2: is there one?. J Clin Microbiol 2020;JCM.00797–20. https://doi.org/10.1128/JCM.00797-20 [Epub ahead of print].
To, KK, Tsang, OT, Leung, WS, Tam, AR, Wu, TC, Lung, DC, et al.. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis 2020;20:565–74. https://doi.org/10.1016/s1473-3099(20)30196-1.
Sethuraman, N, Jeremiah, SS, Ryo, A. Interpreting diagnostic tests for SARS-CoV-2. JAMA 2020;323:2249–51. https://doi.org/10.1001/jama.2020.8259.
Lippi, G, Salvagno, GL, Mattiuzzi, C. Guida sintetica alla diagnostica della malattia da coronavirus 2019 (COVID-19). Biochim Clin 2020;1–6. https://doi.org/10.19186/BC-2020.052 [Epub ahead of print].
Guo, L, Ren, L, Yang, S, Xiao, M, Chang, D, Yang, F, et al.. Profiling early humoral response to diagnose novel coronavirus disease (COVID-19). Clin Infect Dis 2020;1–8. https://doi.org/10.1093/cid/ciaa310 [Epub ahead of print].
Long, QX, Liu, BZ, Deng, HJ, Wu, GC, Deng, K, Chen, YK, et al.. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med 2020;26:845–8. https://10.1038/s41591-020-0897-1.
Padoan, A, Cosma, C, Sciacovelli, L, Faggian, D, Plebani, M. Analytical performances of a chemiluminescence immunoassay for SARS-CoV-2 IgM/IgG and antibody kinetics. Clin Chem Lab Med 2020;58:1081–8. https://doi.org/10.1515/cclm-2020-0443.
Jin, Y, Wang, M, Zuo, Z, Fan, C, Ye, F, Cai, Z, et al.. Diagnostic value and dynamic variance of serum antibody in coronavirus disease 2019. Int J Infect Dis 2020;94:49–52. https://doi.org/10.1016/j.ijid.2020.03.065.
Plebani, M, Padoan, A, Negrini, D, Carpinteri, B, Sciacovelli, L. Diagnostic performances and thresholds: the key to harmonization in serological SARS-CoV-2 assays?. Clin Chim Acta 2020;509:1–7. https://doi.org/10.1016/j.cca.2020.05.050.

Auteurs

Mariarosa Carta (M)

Medicina di Laboratorio, AULSS 8 Berica, Vicenza, Italy.

Luciana Bragagnolo (L)

Microbiologia, AULSS 8 Berica, Vicenza, Italy.

Andrea Tramarin (A)

Cure Primarie-Distretto Est, AULSS 8 Berica, Vicenza, Italy.

Elena Barzon (E)

Medicina di Laboratorio, AULSS 8 Berica, Vicenza, Italy.

Anna Cappelletti (A)

Medicina di Laboratorio, AULSS 8 Berica, Vicenza, Italy.

Michela Pascarella (M)

Microbiologia, AULSS 8 Berica, Vicenza, Italy.

Lauretta Forner (L)

Medicina di Laboratorio, AULSS 8 Berica, Vicenza, Italy.

Maria Grazia Meneghini (MG)

Medicina di Laboratorio, AULSS 8 Berica, Vicenza, Italy.

Chiara Tripodi (C)

Medicina di Laboratorio, AULSS 8 Berica, Vicenza, Italy.

Mario Rassu (M)

Microbiologia, AULSS 8 Berica, Vicenza, Italy.

Davide Giavarina (D)

Medicina di Laboratorio, AULSS 8 Berica, Vicenza, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH